NCT04977674View on ClinicalTrials.gov

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

February 13, 2023

Study Completion Date

February 20, 2023

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

Naltrexone

Pre-treatment with naltrexone 45 min before the ketamine infusion.

DRUG

Placebo

Pre-treatment with placebo 45 min before the ketamine infusion.

DRUG

Ketamine

Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.

Trial Locations (1)

SE58AF

King's College London, London

All Listed Sponsors
lead

King's College London

OTHER

NCT04977674 - Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine | Biotech Hunter | Biotech Hunter